Stempoint Capital LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Stempoint Capital LP reported 52 stock positions worth $313.1 million. Its top holding was Roivant Sciences (ROIV) at 8.3% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 6.3%) and Scholar Rock (SRRK, 5.8%). Compared with Q4 2024, it opened 24 new positions, sold out of 20, added to 12 and reduced 14. The biggest buy was a new position in Arcellx (ACLX) and the biggest sale an exit from Crinetics Pharmaceuticals (CRNX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001952142
- Portfolio Value
- $313.1M (Q1 2025)
- SEC Filing
- 0001420506-25-001189 ↗ filed May 15, 2025
Holdings Value
Holdings 52 stocks · $313.1M
| ROIV Roivant Sciences Ltd. | 8.31% | 2,578,860 | $26.0M | Reduce -4.9% |
| SNDX Syndax Pharmaceuticals Inc. | 6.27% | 1,598,594 | $19.6M | Reduce -44.4% |
| SRRK Scholar Rock Holding Corp. | 5.81% | 566,212 | $18.2M | Add +240.5% |
| ACLX Arcellx Inc. | 5.74% | 273,774 | $18.0M | New |
| MRUS Merus NV | 4.66% | 346,756 | $14.6M | Reduce -43.6% |
| IMVT Immunovant Inc. | 4.66% | 853,472 | $14.6M | Reduce -23.7% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.33% | 40,936 | $13.6M | New |
| NUVL Nuvalent Inc. Class A | 4.31% | 190,401 | $13.5M | Add +31.1% |
| RVMD Revolution Medicines Inc. | 3.60% | 318,782 | $11.3M | Add +64.7% |
| JANX Janux Therapeutics Inc. | 2.95% | 342,062 | $9.2M | Add +134.5% |
| XENE Xenon Pharmaceuticals Inc. | 2.94% | 274,633 | $9.2M | Reduce -26.9% |
| DNLI Denali Therapeutics Inc. | 2.90% | 667,078 | $9.1M | Add +14.2% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.73% | 593,335 | $8.5M | Reduce -7.6% |
| QURE Uniqure NV | 2.48% | 731,039 | $7.7M | Add +712.3% |
| BBIO Bridgebio Pharma Inc. | 2.30% | 208,437 | $7.2M | New |
| CGON CG Oncology Inc. | 2.27% | 289,823 | $7.1M | New |
| SWTX Springworks Therapeutics Inc. | 2.25% | 159,305 | $7.0M | New |
| ARQT Arcutis Biotherapeutics Inc. | 2.20% | 440,073 | $6.9M | Reduce -12.2% |
| INSM Insmed Inc. | 2.12% | 87,059 | $6.6M | Reduce -18.3% |
| ALKS Alkermes PLC | 2.03% | 192,352 | $6.4M | Reduce -53.9% |
| AKRO Akero Therapeutics Inc. | 2.02% | 156,185 | $6.3M | New |
| BHVN Biohaven Ltd. | 1.92% | 250,564 | $6.0M | Add +34.4% |
| CYTK Cytokinetics Inc. | 1.92% | 149,648 | $6.0M | Add +79.1% |
| BPMC Blueprint Medicines Corp. | 1.75% | 61,927 | $5.5M | New |
| VTGN Vistagen Therapeutics Inc. | 1.63% | 2,366,554 | $5.1M | Add +1.6% |
| TARA Protara Therapeutic Inc. | 1.62% | 1,190,579 | $5.1M | Add +258.2% |
| KALV Kalvista Pharmaceuticals Inc. | 1.43% | 386,837 | $4.5M | Reduce -61.0% |
| EWTX Edgewise Therapeutics Inc. | 1.27% | 180,255 | $4.0M | Add +35.8% |
| SRZN Surrozen Inc. | 0.90% | 240,826 | $2.8M | Reduce -31.3% |
| PTGX Protagonist Therapeutics Inc. | 0.76% | 49,241 | $2.4M | Reduce -65.3% |
| ELVN Enliven Therapeutics Inc. | 0.76% | 120,430 | $2.4M | Add +24.5% |
| NBIX Neurocrine Biosciences Inc. | 0.74% | 21,052 | $2.3M | New |
| ASND Ascendis Pharma A/S | 0.73% | 14,732 | $2.3M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.73% | 200,900 | $2.3M | No change |
| SYRE Spyre Therapeutics Inc. | 0.70% | 136,139 | $2.2M | New |
| FOLD Amicus Therapeutics Inc. | 0.70% | 268,919 | $2.2M | New |
| NAMS Newamsterdam Pharma Co. NV | 0.68% | 104,585 | $2.1M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 0.57% | 33,816 | $1.8M | Reduce -83.7% |
| ABUS Arbutus Biopharma Corp. | 0.52% | 467,882 | $1.6M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.49% | 150,000 | $1.5M | No change |
| GERN Geron Corp. | 0.49% | 960,307 | $1.5M | New |
| IDYA Ideaya Biosciences Inc. | 0.35% | 66,999 | $1.1M | New |
| ZLAB Zai Lab Ltd.-ADR | 0.30% | 26,421 | $955K | New |
| OCUL Ocular Therapeutix Inc. | 0.29% | 124,523 | $913K | New |
| DYN Dyne Therapeutics Inc. | 0.28% | 84,430 | $883K | New |
| SLNO Soleno Therapeutics Inc. | 0.25% | 11,155 | $797K | New |
| IFRX Inflarx NV | 0.24% | 725,019 | $740K | New |
| SLDB Solid Biosciences Inc. | 0.23% | 198,150 | $733K | New |
| WVE Wave Life Sciences Ltd. | 0.23% | 89,833 | $726K | Reduce -87.5% |
| MBX MBX Biosciences Inc. | 0.23% | 96,615 | $713K | New |
| SION Sionna Therapeutics Inc. | 0.20% | 60,000 | $628K | New |
| BCAX Bicara Therapeutics Inc. | 0.20% | 47,078 | $613K | New |
Options reported separately and not counted above: EWTX puts ($238K), CVS puts ($165K), MLYS puts ($94K), ARQT calls ($43K), KALV calls ($33K), BBC calls ($17K), RYTM calls ($16K), MRK calls ($8K), NVO calls ($4K).
Portfolio Sells Q4 2024 → Q1 2025
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −4.07 |
| INCY Incyte Corp. | Sold out | 0.00% | −3.35 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -44.4% | 6.27% | −3.25 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −2.59 |
| BMY Bristol-Myers Squibb Co. | Sold out | 0.00% | −2.36 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -83.7% | 0.57% | −2.35 |
| IMVT Immunovant Inc. | Reduce -23.7% | 4.66% | −2.29 |
| WVE Wave Life Sciences Ltd. | Reduce -87.5% | 0.23% | −2.01 |
| MRUS Merus NV | Reduce -43.6% | 4.66% | −1.82 |
| IOVA Iovance Biotherapeutics Inc. | Sold out | 0.00% | −1.76 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −1.75 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −1.34 |
| MLYS Mineralys Therapeutics Inc. | Sold out | 0.00% | −1.24 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −1.14 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −1.08 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −1.07 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −1.07 |
| ALKS Alkermes PLC | Reduce -53.9% | 2.03% | −0.98 |
| CTNM Contineum Therapeutics Inc. Class A | Sold out | 0.00% | −0.98 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.85 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -26.9% | 2.94% | −0.75 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −0.73 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -61.0% | 1.43% | −0.68 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −0.64 |
| PTGX Protagonist Therapeutics Inc. | Reduce -65.3% | 0.76% | −0.61 |
| SRZN Surrozen Inc. | Reduce -31.3% | 0.90% | −0.36 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.33 |
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −0.32 |
| ATYR Atyr Pharma Inc. | Sold out | 0.00% | −0.18 |
| TECX Tectonic Therapeutic Inc. | Sold out | 0.00% | −0.11 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -7.6% | 2.73% | +0.03 |
| ROIV Roivant Sciences Ltd. | Reduce -4.9% | 8.31% | +0.26 |
| INSM Insmed Inc. | Reduce -18.3% | 2.12% | +0.28 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -12.2% | 2.20% | +0.45 |
Portfolio Buys Q4 2024 → Q1 2025
| ACLX Arcellx Inc. | New | 5.74% | +5.74 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 4.33% | +4.33 |
| SRRK Scholar Rock Holding Corp. | Add +240.5% | 5.81% | +4.01 |
| BBIO Bridgebio Pharma Inc. | New | 2.30% | +2.30 |
| CGON CG Oncology Inc. | New | 2.27% | +2.27 |
| SWTX Springworks Therapeutics Inc. | New | 2.25% | +2.25 |
| QURE Uniqure NV | Add +712.3% | 2.48% | +2.08 |
| AKRO Akero Therapeutics Inc. | New | 2.02% | +2.02 |
| BPMC Blueprint Medicines Corp. | New | 1.75% | +1.75 |
| RVMD Revolution Medicines Inc. | Add +64.7% | 3.60% | +1.48 |
| NUVL Nuvalent Inc. Class A | Add +31.1% | 4.31% | +1.46 |
| TARA Protara Therapeutic Inc. | Add +258.2% | 1.62% | +1.18 |
| JANX Janux Therapeutics Inc. | Add +134.5% | 2.95% | +0.99 |
| CYTK Cytokinetics Inc. | Add +79.1% | 1.92% | +0.94 |
| NBIX Neurocrine Biosciences Inc. | New | 0.74% | +0.74 |
| ASND Ascendis Pharma A/S | New | 0.73% | +0.73 |
| SYRE Spyre Therapeutics Inc. | New | 0.70% | +0.70 |
| FOLD Amicus Therapeutics Inc. | New | 0.70% | +0.70 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.68% | +0.68 |
| ABUS Arbutus Biopharma Corp. | New | 0.52% | +0.52 |
| GERN Geron Corp. | New | 0.49% | +0.49 |
| EWTX Edgewise Therapeutics Inc. | Add +35.8% | 1.27% | +0.38 |
| IDYA Ideaya Biosciences Inc. | New | 0.35% | +0.35 |
| ZLAB Zai Lab Ltd.-ADR | New | 0.30% | +0.30 |
| OCUL Ocular Therapeutix Inc. | New | 0.29% | +0.29 |
| DYN Dyne Therapeutics Inc. | New | 0.28% | +0.28 |
| SLNO Soleno Therapeutics Inc. | New | 0.25% | +0.25 |
| IFRX Inflarx NV | New | 0.24% | +0.24 |
| SLDB Solid Biosciences Inc. | New | 0.23% | +0.23 |
| MBX MBX Biosciences Inc. | New | 0.23% | +0.23 |
| ELVN Enliven Therapeutics Inc. | Add +24.5% | 0.76% | +0.21 |
| SION Sionna Therapeutics Inc. | New | 0.20% | +0.20 |
| BCAX Bicara Therapeutics Inc. | New | 0.20% | +0.20 |
| BHVN Biohaven Ltd. | Add +34.4% | 1.92% | +0.18 |
| VTGN Vistagen Therapeutics Inc. | Add +1.6% | 1.63% | +0.14 |
| DNLI Denali Therapeutics Inc. | Add +14.2% | 2.90% | −0.09 |
Options Activity Q4 2024 → Q1 2025
| QQQ Invesco QQQ Trust Series 1 | put | Sold out | 70,000 | $515Kbefore exit |
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 85,000 | $414Kbefore exit |
| EWTX Edgewise Therapeutics Inc. | put | New | 50,000 | $238K |
| SRRK Scholar Rock Holding Corp. | call | Sold out | 100,000 | $228Kbefore exit |
| CVS CVS Health Corp. | put | New | 64,100 | $165K |
| MLYS Mineralys Therapeutics Inc. | put | New | 125,000 | $94K |
| HIMS Hims & Hers Health Inc. | call | Sold out | 75,000 | $75Kbefore exit |
| SNDX Syndax Pharmaceuticals Inc. | call | Sold out | 234,100 | $51Kbefore exit |
| ARQT Arcutis Biotherapeutics Inc. | call | Reduce -93.7% | 100,000 | $43K |
| KALV Kalvista Pharmaceuticals Inc. | call | New | 100,000 | $33K |
| BBC Virtus Biotech Clinical Tria | call | New | 132,500 | $17K |
| RYTM Rhythm Pharmaceuticals Inc. | call | New | 10,000 | $16K |
| MRK Merck & Co. Inc. | call | New | 151,700 | $8K |
| NVO Novo-Nordisk A/S-Spons ADR | call | New | 151,700 | $4K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 73 | $577.9M | TNGX, ABVX, RVMD, ERAS, TYRA |
| Q1 2026Amended | 70 | $520.3M | SRRK, ABVX, SNDX, RVMD, IMVT |
| Q4 2025 | 75 | $582.7M | ABVX, SRRK, CNTA, SNDX, GPCR |
| Q3 2025 | 76 | $495.9M | ROIV, QURE, SRRK, IMVT, DNLI |
| Q2 2025 | 50 | $310.6M | SNDX, IMVT, SRRK, CNTA, MDGL |
| Q1 2025 | 52 | $313.1M | ROIV, SNDX, SRRK, ACLX, MRUS |
| Q4 2024 | 48 | $398.7M | SNDX, ROIV, IMVT, MRUS, CRNX |
| Q3 2024 | 50 | $333.4M | SNDX, ROIV, MRUS, IMVT, ARQT |
| Q2 2024Amended | 42 | $339.9M | SNDX, ROIV, IMVT, CRNX, MRUS |
| Q1 2024Amended | 45 | $374.3M | ROIV, CRNX, SNDX, ARQT, IMVT |